Drugs / Nefopam
Nefopam
English name nefopam
Trials 31
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02174068 | Jul 2014 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04685577 | Jul 2022 → Mar 2026 | — | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT04576078 | Jun 2021 → Dec 2026 expected | — | Hospices Civils de Lyon | Recruiting | No outcome recorded |
| Phase 2/32 trials · 1 met primary | ||||||
| Phase 2/3 | NCT02596269 | Oct 2012 → Sep 2013 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT00413257 | Dec 2006 → Dec 2007 | chronic pain syndrome | University Hospital, Bordeaux | Completed | Met primary |
| Phase 35 trials · 1 met primary | ||||||
| Phase 3 | NCT06349798 | Apr 2024 → Sep 2026 overdue | — | University Hospital, Tours | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05648058 | Dec 2022 → Oct 2023 | — | Ministry Of Health / Nineveh Health Directorate | Unknown | No outcome recorded |
| Phase 3 | NCT05071352 | Oct 2021 → Mar 2023 | — | Cairo University | Completed | Met primary |
| Phase 3 | NCT04622813 | Apr 2021 → Oct 2022 | gallbladder disorder, neuropathy, painful, substance-related disorder | American University of Beirut Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01577407 | Sep 2011 → May 2012 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 48 trials · 2 missed | ||||||
| Phase 4 | NCT07826988 | Oct 2026 → Oct 2029 expected | sickle cell disease | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07491393 | Apr 2026 → Apr 2027 expected | — | University Hospital, Rouen | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07423650 | Mar → Oct 2026 expected | — | Iuliu Hatieganu University of Medicine and Pharmacy | Recruiting | Missed primary |
| Phase 4 | NCT05825560 | May 2023 → Jun 2026 | — | Nîmes University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04241640 | Sep 2020 → Aug 2022 | — | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT01882530 | Jul 2013 → Jan 2016 | — | Rennes University Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01543165 | Dec 2012 → Dec 2013 | urinary tract obstruction | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00639574 | Mar → Nov 2008 | ureterolithiasis | University Hospital, Clermont-Ferrand | Completed | Missed primary |
| Phase not applicable13 trials · 1 met primary · 1 missed | ||||||
| — | NCT05173337 | Dec 2021 → Sep 2022 | lung cancer | Kangbuk Samsung Hospital | Completed | Met primary |
| — | NCT04450355 | Jul 2020 → Aug 2021 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT03955705 | May 2019 → Apr 2021 | cervical disk degenerative disorder | Mahidol University | Unknown | No outcome recorded |
| — | NCT02949310 | Oct 2016 → Dec 2018 | breast cancer | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
| — | NCT02577068 | Nov 2015 → Aug 2016 | thyroid gland disorder | Yonsei University | Completed | No outcome recorded |
| — | NCT02561494 | Jun 2015 → Aug 2016 | gastric neoplasm | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| — | NCT02561468 | Apr 2015 → Jan 2016 | breast neoplasm | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| — | NCT01833728 | Apr 2013 → Jan 2014 | kidney neoplasm | Yonsei University | Completed | No outcome recorded |
| — | NCT01808014 | Feb 2013 → Mar 2014 | vertebral column disorder | Yonsei University | Unknown | No outcome recorded |
| — | NCT01732666 | May → Sep 2012 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT01461031 | Oct 2011 → Sep 2012 | — | The Catholic University of Korea | Completed | No outcome recorded |
| — | NCT00874172 | Oct 2009 → Oct 2012 | sickle cell disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT03619538 | Jun 2007 | colonic neoplasm | Nîmes University Hospital | Completed | Missed primary |
| Comparator or background therapy21 trials | ||||||
| Phase 0 | NCT06680609 Comparator | Jun → Dec 2023 | — | King Abdullah University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT05129137 Comparator | Nov → Dec 2021 | — | Unither Pharmaceuticals, France | Completed | No outcome recorded |
| Phase 2 | NCT02441673 Comparator | Oct 2018 → Jan 2019 | benign shuddering attacks | Lagos State Health Service Commission | Unknown | No outcome recorded |
| Phase 2 | NCT01703351 Comparator | Oct 2012 → Nov 2015 | lung neoplasm | Yonsei University | Completed | No outcome recorded |
| Phase 2/3 | NCT03626753 Comparator | Jan → Jun 2015 | puerperal infection | Centre de Maternité de Monastir | Completed | No outcome recorded |
| Phase 3 | NCT07414706 Background | Mar 2026 → Jun 2028 expected | local anesthetic poisoning | Centre Hospitalier Universitaire, Amiens | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06381063 Background | Mar 2024 → Mar 2027 expected | — | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| Phase 3 | NCT04622735 Comparator | Feb 2020 → Oct 2022 | — | Unither Pharmaceuticals, France | Completed | No outcome recorded |
| Phase 3 | NCT02444897 Comparator | Sep 2013 → Dec 2014 | gastric cancer | Keimyung University Dongsan Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04870541 Comparator | Dec 2020 → Jun 2021 | benign shuddering attacks | Saint-Joseph University | Unknown | No outcome recorded |
| Phase 4 | NCT04110665 Comparator | Sep 2017 → Sep 2019 | disease of the tendon | Nîmes University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02493231 Comparator | Mar → Dec 2015 | cholecystitis | Hallym University Kangnam Sacred Heart Hospital | Unknown | No outcome recorded |
| — | NCT06627816 Comparator | Jan → Jun 2025 | benign shuddering attacks | Kasr El Aini Hospital | Completed | No outcome recorded |
| — | NCT05673486 Background | Mar → Dec 2023 | — | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer | Completed | No outcome recorded |
| — | NCT05861791 Comparator | Feb 2023 → Jul 2024 | — | Chung-Ang University Gwangmyeong Hospital | Completed | No outcome recorded |
| — | NCT07207304 Comparator | Feb 2022 → Mar 2023 | hepatocellular carcinoma | Iuliu Hatieganu University of Medicine and Pharmacy | Completed | No outcome recorded |
| — | NCT04491786 Background | Aug 2020 → May 2021 | — | Gia Dinh People Hospital | Completed | No outcome recorded |
| — | NCT03462836 Comparator | Apr → Dec 2019 | colorectal cancer | Yonsei University | Withdrawn | No outcome recorded |
| — | NCT03130010 Comparator | Mar → Dec 2017 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT01622881 Comparator | Jun 2012 → Jul 2013 | — | Severance Hospital | Completed | No outcome recorded |
| — | NCT03122665 Comparator | Aug 2004 → Jan 2006 | — | The Cleveland Clinic | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 55 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nefopam | “Thirty minutes before the end of surgery, nefopam 40 mg, paracetamol 1 g, and ketoprofen 100 mg will be administered intravenously, depending on the patient's comorbidities,...” NCT07207304 ↗52“Intraoperative time: intravenous ketamine 0.5 mg kg-1, intravenous dexamethasone 8 mg Postoperative time: paracetamol 1 g every 6 hours a day, nefopam 20 every 8 hours a day,...” NCT06381063 ↗ “initially receiving nefopam and tramadol, implementing with ketamine if patients remain painful, and then implementing with remifentanil with escalating doses in case of...” PMID 39832962 ↗ Jan 2025 “Multimodal analgesia is administered to patients as follows : 2-3 mg of morphine (2mg if patient's weight \<60kg; 3mg if patient's weight \>60kg) + Paracetamol 1g/8h and...” NCT05673486 ↗ “The aim of this study was to estimate the effect of adding nefopam to ketoprofen upon subsequent morphine consumption and the time needed to achieve adequate analgesia in renal colic.” PMID 22427403 ↗ Mar 2012 “IV PCA (fentanyl 10mcg/kg + nefopam (Acupan®) 80mg + Ramosetron (Nasea®) ) apply 30min before end of surgery.” NCT03462836 ↗ “1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar” NCT00874172 ↗ “Paracetamol 1 g; Nefopam (Acupan) 20 mg; Parecoxib 40 mg” NCT07414706 ↗ “Nefopam is a central analgesic.” NCT04491786 ↗ “Drug: néfopam” NCT00413257 ↗ “Nefopam 20mg” NCT02577068 ↗ |
| Known as | Acupan | “The nefopam group received 120 mg nefopam (Acupan, Pharmbio, France) by continuous iv infusion over the study period (48h)” NCT03619538 ↗4“"Nefopam (Acupan)" 20 MG/ML Injectable Solution” NCT03626753 ↗ “Nefopam (Acupan) 20 mg” NCT07414706 ↗ “nefopam (Acupan®) 80mg” NCT03462836 ↗ |
| Known as | fenazocine | “Nefopam (NFP) is a non-opioid, non-steroidal, centrally acting analgesic drug that is derivative of the non-sedative benzoxazocine, developed and known in 1960s as fenazocine.” PMID 24748937 ↗ Mar 2014 |
| Known as | Nefopam hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL465026 ↗ |
| Known as | NEFOPAM HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL465026 ↗ |
| Known as | NFP | “Nefopam (NFP) is a non-opioid, non-steroidal, centrally acting analgesic drug” PMID 24748937 ↗ Mar 2014 |
| Known as | Nopain | “Group N (n=80) will receive nefopam 0.15 mg/kg i.v. (Nopain®, Medical Union Pharmaceuticals MUP, Ismailia, Egypt, Ampoules of 20 mg/1 ml)” NCT06627816 ↗ |
| Known as | NSC-757856 | ChEMBL registry synonym — accepted as the source's own label CHEMBL465026 ↗ |
| Action | Inhibit | “Nefopam can inhibit serotonin, dopamine, and norepinephrine reuptake through central mechanisms.” NCT01622881 ↗ |
| Modality | Small molecule | — CHEMBL465026 ↗ |
| Route | Intravenous | “0,3mg/kg IV bolus preoperative and 65 µg/kg/h during H48 postoperative” NCT00413257 ↗ |